Black Diamond Therapeutics, Inc. reported an insider ownership change involving Ali Behbahani in a Form 4 filed June 29, 2026, covering a transaction dated June 26, 2026. The filing indicates a change in Behbahani’s beneficial ownership of derivative securities of Black Diamond Therapeutics, which trades under the ticker BDTX. The reported action appears to involve a stock option award. The filing’s explanatory note states that the shares subject to the option will vest and become exercisable in full on the earlier of two dates: June 26, 2027, or the company’s next annual meeting of stockholders. Vesting is contingent on Behbahani’s continued service through the applicable vesting date. The excerpt provided does not include the transaction table details typically found in a Form 4, such as the number of option shares granted, the exercise price, the transaction code, or the total number of derivative securities beneficially owned after the transaction. As a result, the precise size and economic terms of the option award cannot be determined from the available text. The filing was signed on Behbahani’s behalf by Zachary Bambach, attorney-in-fact, on June 29, 2026. In practical terms, the report signals an equity-based compensation or incentive award rather than an open-market purchase or sale, with vesting tied either to the one-year anniversary of the grant date or the next shareholder meeting, whichever comes first.